Diamyd Medical Drug Delays Insulin Need by Over Five Years
New data published by Diamyd Medical shows its drug retogatein delayed the need for insulin by an average of 5.6 years in treatment responders. The findings come from a diabetes prevention trial.
Swedish company Diamyd Medical announced that its drug candidate, retogatein, has shown significant results in delaying the onset of insulin dependence in a recent study. The published data from a randomized, placebo-controlled trial indicate that retogatein delayed the need for insulin by 5.6 years in the group of patients who responded to the treatment.
The research focused on the prevention of type 1 diabetes. While retogatein does not yet prevent the disease entirely, the results suggest it can substantially slow its progression. CEO Anders Essen-Möller stated that the drug has demonstrated a favorable safety profile and is simple to administer, potentially offering a "game-changing" approach.
These findings could mark a significant step forward in managing autoimmune diabetes. Delaying the need for insulin therapy can improve patients' quality of life and reduce the long-term complications associated with the disease. The diabetes research field has been actively seeking interventions to slow or halt the progression of type 1 diabetes.
Diamyd Medical plans to continue its research and development efforts with retogatein, aiming to offer new therapeutic options for individuals with type 1 diabetes. Further clinical studies are expected to validate these findings and explore the drug's broader application.